Free accessBrief reportFirst published online 2015-11
Technical Appendix. Calculations Used to Estimate the Size and Direct Medical Cost of Screening,Testing,and Treatment Services for the Safety Net Population for Sexually Transmitted Disease Prevention,United States,2013–2023
GrovesRMMosherWDLepkowskiJMKirgisNG, Planning and development of the continuous National Survey of Family Growth. Vital Health Stat12009(48).
4.
LepkowskiJMMosherWDGrovesRMWestBTWagnerJGuH.Responsive design, weighting, and variance estimation in the 2006–2010 National Survey of Family Growth. Vital Health Stat22013(158).
GiftTLGaydosCAKentCKMarrazzoJMRietmeijerCASchillingerJA, The program cost and cost-effectiveness of screening men for chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis2008;35(11 Suppl):S66–75.
10.
Owusu-EduseiKJrDoshiSRAptBSGiftTL, The direct cost of chlamydial infections: Estimates for the employer-sponsored privately insured population in the United States, 2003–2007 [published erratum appears in Sex Transm Dis 2011;38:888]. Sex Transm Dis2010;37:519–21.
11.
SatterwhiteCLTorroneEMeitesEDunneEFMahajanROcfemiaMC, Sexually transmitted infections among U.S. women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis2013;40:187–93.
12.
HosenfeldCBWorkowskiKABermanSZaidiAADysonJMosureD, Repeat infection with chlamydia and gonorrhea among females: A systematic review of the literature. Sex Transm Dis2009;36:478–89.
13.
FungMScottKCKentCKKlausnerJD, Chlamydia and gonococcal reinfection among men: A systematic review of data to evaluate the need for retesting. Sex Transm Infect2007;83:304–9.
14.
Bureau of Labor Statistics. Consumer price index [cited 2015 Apr 20. Available from: URL: http://www.bls.gov/cpi.